4basebio PLC Stocks

4basebio PLC and its affiliated entities are dedicated to the research, development, production, and commercialization of synthetic DNA and RNA compounds, in addition to non-viral vector technologies. Their operations span across Europe, the United States, and other global markets. The company's innovative product portfolio includes: hpDNA: A unique double-stranded linear DNA featuring covalently closed hairpin structures at its ends, suitable for diverse viral and non-viral vector uses. opDNA: This partially opened, linear, double-stranded DNA is specifically engineered for in vitro transcription processes, enabling the generation of mRNA for vaccines and therapeutic applications. oeDNA (open-ended DNA): A linear, double-stranded DNA product optimally suited for advanced genome editing techniques. osDNA (open stabilized DNA): This product integrates specific nucleotide modifications within its DNA backbone, allowing for the precise modulation of its immunostimulatory properties, which is crucial for DNA vaccine development. The Hermes: A proprietary delivery system for nucleic acids and protein payloads, renowned for offering a thermo-stable alternative to conventional lipid-based delivery platforms. Established in 2008 and headquartered in Cambridge, United Kingdom, 4basebio PLC was formerly known as 4basebio UK Societas, adopting its current name in July 2021.